Weekend update with some charts, $AVEO $ATRS $ARNA $ACRX briefly covered. Market forecast and opinion. YouTube Video
Tag: stocks
Updated: (cleaned up) Market Historical Chart For Review: Economic Commentary and Market Forecast Opinion.
Above, we can see an historical chart of The Dow going back to 2003. Take note of the current market trend and compare to past trends. I feel the market needs a correction and is over extended on the QE…
Antares Pharma ($ATRS) Technical Long Trade Thesis and Chart
Antares Pharma (ATRS) is being set up to run to at least $3.85, Thesis follows below; The chart above shows “quiet” accumulation. The purple line is the accumulation, notice for the first time, the accumulation points up, MACDÂ and RSI…
AcelRx Pharma Selloff Caused By Error In Recent Press Release
On March 12th, Acelrx (ACRX) released a pr covering its last quarter’s earnings. In the pr, the company stated that it had cash to last only to Q3 of this year. However, in the official conference call minutes, the company…
UPDATED: Cyclacel Pharma: Undervalued With Its Potential Blockbuster Drug
Cyclacel Pharmaceuticals (NASDAQ: CYCC) is a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. Cyclacel’s strategy is to build a diversified biopharmaceutical business focused in hematology and…
DARA Poised to Break Out on Catalysts
DARA Biosciences (NASDAQ: DARA) is expecting to hear soon on the status of its Orphan Drug application submitted to The Food and Drug Administration (FDA) in November of last year for its drug KRN5500, which is being studied for the…
4 Small Cap Biopharmas With Near-Term Catalysts
To begin this week, I list four biopharma companies I feel have significant catalysts coming up. According to investinganswers.com a catalyst is defined as news or information that changes a pricing trend in a security. Catalysts can drive an investment…
Pozen: An Undervalued Investment And Catalyst Trade Opportunity
Small cap biopharmas that make for good long term investments are hard to find. Most small cap biopharmas burn a ton of cash while developming treatments for a variety of ailments and rare diseases. Today, we focus on Pozen (NASDAQ:POZN)…
The Obesity Epidemic – EnteroMedics New Treatment Approach
Our focus turns to EnteroMedics (NASDAQ:ETRM), which offers a new treatment approach currently in Phase III clinical trials, designed to help morbidly obese people lose weight. EnteroMedics’ approach may be a better solution for people who see little or no…
UPDATED: EnteroMedics (ETRM) Basic DD and Thesis
EnteroMedics Inc. (ETRM) I bought a nice amount of shares. Catalyst trade run up target opinion: $.4.40. Positive data release: Gap to $7. 1 year: $15 (my opinions only) According to company press releases, conference calls, and my correspondence with…
